Psoriasis Clinical Trial

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

Summary

This is an open-label, long-term safety study of roflumilast (ARQ-151) 0.3% cream in subjects with chronic plaque psoriasis involving up to 25% total Body Surface Area (BSA). Study medication will be applied by the qualifying subjects topically once daily for 52 weeks at home. Periodic clinic visits will include assessments for clinical safety, application site reactions, and disease improvement or progression.

View Full Description

Full Description

Cohort 1 of this study consisted of participants who previously completed study ARQ-151-201 (NCT03638258), and Cohort 2 consisted of participants who were not previously enrolled in ARQ-151-201.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants legally competent to sign and give informed consent
Males and females ages 18 years and older
Subjects with chronic plaque psoriasis who met eligibility criteria for ARQ-151-201, successfully completed ARQ-151-201 through Week 12, and are able to enroll into this long-term safety study on the Week 12 visit of the previous study (ARQ-151-201).
Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at all study visits. In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial. Highly effective forms of contraception include: oral/implant/injectable/transdermal contraceptives, intrauterine device, or partner's vasectomy. If barrier methods are used (e.g., condom with spermicide, diaphragm with spermicide), then 2 forms of conception are required. The use of abstinence as a contraceptive measure is acceptable as long as this is a consistent part of a lifestyle choice and a backup method has been identified if the subject becomes sexually active.
Post-menopausal women with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization (permanent sterilization methods include hysterectomy, bilateral oophorectomy, hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy).

Exclusion Criteria:

Subjects who experienced an ARQ-151 treatment-related AE or a serious AE (SAE) that precluded further treatment with ARQ-151 cream in Study ARQ-151-201.
Subjects that use any Excluded Medications and Treatments
Current diagnosis of guttate, erythrodermic/exfoliative, palmoplantar, or pustular psoriasis.
Subjects who cannot discontinue the use of strong P-450 cytochrome inhibitors e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, suboxone and telithromycin during the study period.
Subjects who cannot discontinue the use of strong P-450 cytochrome inducers e.g., efavirenz, nevirapine, glucocorticoids, barbiturates (including phenobarbital), phenytoin, and rifampin during the study period.

Known or suspected:

severe renal insufficiency or severe hepatic disorders
hypersensitivity to component(s) of the investigational products
history of severe depression, suicidal ideation
Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.
Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

332

Study ID:

NCT03764475

Recruitment Status:

Completed

Sponsor:

Arcutis Biotherapeutics, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 30 Locations for this study

See Locations Near You

Arcutis Clinical Site 35
Beverly Hills California, 90212, United States
Arcutis Clinical Site 29
Northridge California, 91324, United States
Arcutis Clinical Site 28
San Diego California, 92123, United States
Arcutis Clinical Site 27
Santa Monica California, 90403, United States
Arcutis Clinical Site 12
Miami Florida, 33144, United States
Arcutis Clinical Site 16
Sanford Florida, 32771, United States
Arcutis Clinical Site 21
Louisville Kentucky, 40217, United States
Arcutis Clinical Site 34
Clinton Township Michigan, 48038, United States
Arcutis Clinical Site 33
Detroit Michigan, 48202, United States
Arcutis Clinical Site 20
Fridley Minnesota, 55432, United States
Arcutis Clinical Site 22
New York New York, 10029, United States
Arcutis Clinical Site 14
High Point North Carolina, 27262, United States
Arcutis Clinical Site 39
Bexley Ohio, 43209, United States
Arcutis Clinical Site 15
Pittsburgh Pennsylvania, 15213, United States
Arcutis Clinical Site 19
College Station Texas, 77845, United States
Arcutis Clinical Site 37
Houston Texas, 77004, United States
Arcutis Clinical Site 13
Houston Texas, 77056, United States
Arcutis Clinical Site 23
San Antonio Texas, 78213, United States
Arcutis Clinical Site 24
Webster Texas, 77598, United States
Arcutis Clinical Site 31
Norfolk Virginia, 23502, United States
Arcutis Clinical Site 18
Surrey British Columbia, V3R 6, Canada
Arcutis Clinical Site 11
Surrey British Columbia, V3V 0, Canada
Arcutis Clinical Site 38
Winnipeg Manitoba, R3M 3, Canada
Arcutis Clinical Site 10
Ajax Ontario, L1S 7, Canada
Arcutis Clinical Site 25
London Ontario, N6H 5, Canada
Arcutis Clinical Site 26
Markham Ontario, L3P 1, Canada
Arcutis Clinical Site 32
Oakville Ontario, L6J 7, Canada
Arcutis Clinical Site 17
Peterborough Ontario, K9J 5, Canada
Arcutis Clinical Site 30
Waterloo Ontario, N2J 1, Canada
Arcutis Clinical Site 36
Windsor Ontario, N8W 1, Canada

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 2

Estimated Enrollment:

332

Study ID:

NCT03764475

Recruitment Status:

Completed

Sponsor:


Arcutis Biotherapeutics, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.